NEW YORK, November 4, 2016 /PRNewswire/ --
On Thursday, the NASDAQ Composite ended the trading session at 5,058.41, down 0.92%; the Dow Jones Industrial Average edged 0.16% lower, to finish at 17,930.67; and the S&P 500 closed at 2,088.66, down 0.44%. Stock-Callers.com looks at the performance of the following Biotech stocks as the US markets continue to display some bearish sentiment: Ocular Therapeutix Inc. (NASDAQ: OCUL), Idera Pharmaceuticals Inc. (NASDAQ: IDRA), Conatus Pharmaceuticals Inc. (NASDAQ: CNAT), and Infinity Pharmaceuticals Inc. (NASDAQ: INFI). Download the free research reports on these stocks today:
Bedford, Massachusetts headquartered Ocular Therapeutix Inc.'s stock fell 9.24%, to close the day at $4.91. The stock recorded a trading volume of 970,106 shares. Shares of the Company, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, are trading 26.09% and 36.74% below its 50-day and 200-day moving averages, respectively. Additionally, the stock has a Relative Strength Index (RSI) of 25.89. See our free and comprehensive research report on OCUL at:
Cambridge, Massachusetts-based Idera Pharmaceuticals Inc.'s stock finished Thursday's session 7.01% lower at $1.46 with a total trading volume of 1.10 million shares. Shares of the Company, which focuses on the discovery, development, and commercialization of therapeutics for oncology and rare diseases in the US, are trading below its 50-day and 200-day moving averages by 29.26% and 19.82%, respectively. Idera Pharmaceuticals' stock has an RSI of 33.32. IDRA free research report PDF is just a click away at:
On Thursday, shares in San Diego, California headquartered Conatus Pharmaceuticals Inc. recorded a trading volume of 211,031 shares. The stock ended the day 5.06% lower at $1.50. Shares of Conatus Pharma, which focuses on the development and commercialization of novel medicines to treat liver diseases in the US, are trading below its 50-day and 200-day moving averages by 21.45% and 29.19%, respectively. Furthermore, Conatus Pharma's shares have an RSI of 28.90. Sign up for your complimentary report on CNAT at:
On Thursday, shares in Cambridge, Massachusetts headquartered Infinity Pharmaceuticals Inc. ended the session 12.93% lower at $1.01 with a total trading volume of 818,155 shares. Shares of Infinity Pharma, which discovers, develops, and delivers medicines to patients with difficult-to-treat diseases, are trading at a PE ratio of 3.48. The stock is trading 30.58% below its 50-day moving average and 72.14% below its 200-day moving average. Moreover, shares of the Company have an RSI of 22.11. Register for free on Stock-Callers.com and download the latest research report on INFI at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email email@example.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: +44 330 808 3765
Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA